Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32,800 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo oral tablet Clear all
Completed Phase 1Phase 2 Interventional

Use of a Nutritional Supplement to Treat Diabetic Symptoms in HIV-Infected Adults

NCT00109746
View directory record Official record
Conditions
Insulin Resistance, HIV Infections
Interventions
chromium picolinate
Dietary Supplement
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 22, 2026, 2:36 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

NCT04064346
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney, ADPKD
Interventions
Lixivaptan, Placebo
Drug
Lead sponsor
Palladio Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Hoover, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 22, 2026, 2:36 PM EDT
Completed Phase 2 Interventional Results available

To Study GSP 301 in Patients With Seasonal Allergic Rhinitis

NCT02318303
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
GSP 301-1 NS (QD), GSP 301-2 NS (BID), GSP 301 Placebo NS, Olopatadine HCl-1 NS (QD), Olopatadine HCl-2 NS (BID), Mometasone Furoate-1 NS (QD), Mometasone Furoate-2 NS (BID)
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years and older
Enrollment
1,111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 22, 2026, 2:36 PM EDT
Completed Phase 2 Interventional

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

NCT00112073
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
bapineuzumab, placebo
Drug · Other
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
26
States / cities
Sun City, Arizona • Irvine, California • Los Alamitos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Oct 22, 2026, 2:36 PM EDT
Not listed Phase 2 Interventional

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

NCT06225973
View directory record Official record
Conditions
Dry Eye Disease
Interventions
TL-925, Placebo
Drug · Other
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
18
States / cities
Phoenix, Arizona • Glendale, California • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 22, 2026, 2:36 PM EDT
Active, not recruiting Phase 2 Interventional

Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer

NCT05947383
View directory record Official record
Conditions
Cancer, Major Depressive Disorder
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Sunstone Medical
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 2:36 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bupivacaine for Post-operative Pain in Mohs

NCT04362566
View directory record Official record
Conditions
Pain, Postoperative, Narcotic Use
Interventions
Bupivacaine, Placebo Saline
Drug · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 2:36 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

NCT07225556
View directory record Official record
Conditions
Overweight, Obesity
Interventions
LY4167586, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 22, 2026, 2:36 PM EDT
Recruiting Phase 2 Interventional

Cannabidiol for Reducing Cigarette Use

NCT06218056
View directory record Official record
Conditions
Tobacco Use Disorder, Tobacco Smoking, Tobacco Dependence
Interventions
Cannabidiol (CBD) 800 mg, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
North Hollywood, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 22, 2026, 2:36 PM EDT
Not listed Phase 3 Interventional

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

NCT02847429
View directory record Official record
Conditions
GIST With D842V Mutated PDGFRA Gene
Interventions
Crenolanib, Placebo
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Santa Monica, California • Miami, Florida • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 22, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU

NCT01889862
View directory record Official record
Conditions
Phenylketonuria (PKU)
Interventions
BMN165 20mg/day, BMN165 40mg/day, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 70 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
29
States / cities
La Jolla, California • Oakland, California • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 22, 2026, 2:36 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

NCT00842088
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Placebo, HQK-1001
Drug
Lead sponsor
HemaQuest Pharmaceuticals Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
8
States / cities
Madison, Alabama • Oakland, California • Daytona Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2011 · Synced Oct 22, 2026, 2:36 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

NCT04725188
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
Pembrolizumab/Vibostolimab coformulation, Docetaxel, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 22, 2026, 2:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Trial to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults

NCT05428761
View directory record Official record
Conditions
Dehydration, Rehydration, Exercise Performance, Exercise Recovery, Fluid Balance, Cognitive Performance
Interventions
TP1, TP2, Placebo
Other
Lead sponsor
Liquid I.V.
Other
Eligibility
18 Years to 49 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 22, 2026, 2:36 PM EDT
Withdrawn Phase 2 Interventional

Intramuscular Ketamine for Suicidal Ideation

NCT05105061
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Ketamine (Ketalar), Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 22, 2026, 2:36 PM EDT
Withdrawn Phase 2 Interventional

Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis

NCT00279461
View directory record Official record
Conditions
Arthritis, Rheumatoid, Vitamin D Deficiency
Interventions
Placebo in arm A and Vitamin D in arm B, vitamin D 3 for arm A ,and matching placebo for arm B
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 22, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects

NCT04880642
View directory record Official record
Conditions
COVID-19
Interventions
C21, Placebo
Drug
Lead sponsor
Vicore Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Orange, California • Winfield, Illinois • Fort Wayne, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 22, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)

NCT05890586
View directory record Official record
Conditions
Covid19
Interventions
Fluvoxamine, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
91
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 22, 2026, 2:36 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Prevention of Severe Postpartum Hypertension

NCT02450773
View directory record Official record
Conditions
Hypertension
Interventions
Furosemide, Potassium chloride, Placebo #1, Placebo #2
Drug
Lead sponsor
Indiana University
Other
Eligibility
Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 22, 2026, 2:36 PM EDT
Withdrawn Phase 3 Interventional

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

NCT00338273
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Timeline
2006 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 22, 2026, 2:36 PM EDT
Recruiting Phase 4 Interventional

Tirzepatide in Idiopathic Intracranial Hypertension Trial

NCT07191873
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension (IIH)
Interventions
Tirzepatide, Tirzepatide Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

NCT02371369
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumor
Interventions
Pexidartinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
19
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 22, 2026, 2:36 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars

NCT02161354
View directory record Official record
Conditions
Dental Pain
Interventions
NTC-510 capsules, Placebo Capsules, NTC-510A Capsules
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 22, 2026, 2:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants

NCT02717754
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Little Rock, Arkansas • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 22, 2026, 2:36 PM EDT